Literature DB >> 27796165

Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection.

Florence Huguet1,2, Carla Hajj2, Corrine B Winston3, Weiji Shi4, Zhigang Zhang4, Abraham J Wu2, Eileen M O'Reilly5, Diane L Reidy5, Peter Allen6, Karyn A Goodman7.   

Abstract

BACKGROUND: To assess local control, survival and conversion to resectability among locally advanced pancreatic cancer (LAPC) patients treated with induction chemotherapy (ICT) followed by chemoradiotherapy treatment using intensity-modulated radiation therapy (IMRT).
MATERIAL AND METHODS: Between 2007 and 2012, 134 LAPC patients were treated with ICT followed by IMRT. After chemoradiotherapy, 40 patients received maintenance chemotherapy.
RESULTS: With a median follow-up of 20 months, median overall survival (OS) was 23 months. One- and two-year OS was 85% and 47%, respectively. On multivariate analysis, progression of disease after IMRT was associated with worse OS. Cumulative incidence of local failure was 10% at one year and 36% at two years. Twenty-six patients (19%) underwent resection after chemoradiotherapy including 22 patients (85%) with negative margins. On multivariate analysis, response to IMRT was associated with surgery (p = .01). Acute grade 3-4 hematologic and non-hematologic toxicity rates were 26% and 4.5%, respectively.
CONCLUSION: IMRT is safe in patients with LAPC. Patients with non-progressive LAPC after ICT and who received IMRT had high rates of local control and prolonged survival.

Entities:  

Mesh:

Year:  2016        PMID: 27796165      PMCID: PMC5644019          DOI: 10.1080/0284186X.2016.1245862

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  28 in total

1.  FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Authors:  Jason E Faris; Lawrence S Blaszkowsky; Shaunagh McDermott; Alexander R Guimaraes; Jackie Szymonifka; Mai Anh Huynh; Cristina R Ferrone; Jennifer A Wargo; Jill N Allen; Lauren E Dias; Eunice L Kwak; Keith D Lillemoe; Sarah P Thayer; Janet E Murphy; Andrew X Zhu; Dushyant V Sahani; Jennifer Y Wo; Jeffrey W Clark; Carlos Fernandez-del Castillo; David P Ryan; Theodore S Hong
Journal:  Oncologist       Date:  2013-05-08

2.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Authors:  Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

3.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

4.  Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.

Authors:  Sunil Krishnan; Awalpreet S Chadha; Yelin Suh; Hsiang-Chun Chen; Arvind Rao; Prajnan Das; Bruce D Minsky; Usama Mahmood; Marc E Delclos; Gabriel O Sawakuchi; Sam Beddar; Matthew H Katz; Jason B Fleming; Milind M Javle; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-11       Impact factor: 7.038

5.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

Authors:  Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

6.  Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.

Authors:  Michael T Milano; Steven J Chmura; Michael C Garofalo; Carla Rash; John C Roeske; Phillip P Connell; Oh-Hoon Kwon; Ashesh B Jani; Ruth Heimann
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

7.  FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.

Authors:  L Marthey; A Sa-Cunha; J F Blanc; M Gauthier; A Cueff; E Francois; I Trouilloud; D Malka; J B Bachet; R Coriat; E Terrebonne; C De La Fouchardière; S Manfredi; D Solub; C Lécaille; A Thirot Bidault; F Carbonnel; J Taieb
Journal:  Ann Surg Oncol       Date:  2014-07-19       Impact factor: 5.344

8.  Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.

Authors:  C H Crane; J A Antolak; I I Rosen; K M Forster; D B Evans; N A Janjan; C Charnsangavej; P W Pisters; R Lenzi; M A Papagikos; R A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2001

9.  Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.

Authors:  Yong-Rui Bai; Guo-Hua Wu; Wei-Jian Guo; Xu-Dong Wu; Yuan Yao; Yin Chen; Ren-Hua Zhou; Dong-Qin Lu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

10.  A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.

Authors:  Andrew H Ko; Jeanne M Quivey; Alan P Venook; Emily K Bergsland; Elizabeth Dito; Brian Schillinger; Margaret A Tempero
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-23       Impact factor: 7.038

View more
  9 in total

1.  Conversion surgery only for highly selected patients with unresectable pancreatic cancer: a satisfactory outcome in exchange for a lower resection rate.

Authors:  Seiji Natsume; Yasuhiro Shimizu; Yoshiki Senda; Susumu Hijioka; Keitaro Matsuo; Seiji Ito; Koji Komori; Tetsuya Abe; Kazuo Hara
Journal:  Surg Today       Date:  2019-02-07       Impact factor: 2.549

2.  Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis.

Authors:  Xing Chen; Geng Liu; Kaiqiang Wang; Guodong Chen; Jinjin Sun
Journal:  Oncotarget       Date:  2017-07-18

3.  Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft.

Authors:  Eunsung Jun; Song Cheol Kim; Chan Mi Lee; Juyun Oh; Song Lee; In Kyong Shim
Journal:  Sci Rep       Date:  2017-09-28       Impact factor: 4.379

4.  Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer.

Authors:  Sarah Stefanowicz; Kristin Stützer; Sebastian Zschaeck; Annika Jakobi; Esther G C Troost
Journal:  Radiat Oncol       Date:  2018-11-22       Impact factor: 3.481

5.  Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer.

Authors:  Soumon Rudra; Naomi Jiang; Stephen A Rosenberg; Jeffrey R Olsen; Michael C Roach; Leping Wan; Lorraine Portelance; Eric A Mellon; Anna Bruynzeel; Frank Lagerwaard; Michael F Bassetti; Parag J Parikh; Percy P Lee
Journal:  Cancer Med       Date:  2019-04-01       Impact factor: 4.452

6.  Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers.

Authors:  John M David; Sungjin Kim; Veronica R Placencio-Hickok; Arman Torosian; Andrew Hendifar; Richard Tuli
Journal:  Adv Radiat Oncol       Date:  2018-11-09

7.  Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation.

Authors:  Comron Hassanzadeh; Soumon Rudra; Ani Bommireddy; William G Hawkins; Andrea Wang-Gillam; Ryan C Fields; Bin Cai; Justin Park; Olga Green; Michael Roach; Lauren Henke; Hyun Kim
Journal:  Adv Radiat Oncol       Date:  2020-06-25

8.  Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical.

Authors:  Sarah Stefanowicz; Waldemar Wlodarczyk; Susanne Frosch; Sebastian Zschaeck; Esther G C Troost
Journal:  Clin Transl Radiat Oncol       Date:  2020-12-09

9.  Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer.

Authors:  Eun Sang Oh; Tae Hyun Kim; Sang Myung Woo; Woo Jin Lee; Ju Hee Lee; Sang Hee Youn; Sung Sik Han; Sang Jae Park; Dae Yong Kim
Journal:  Radiat Oncol J       Date:  2018-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.